Abstract
Discrete chemical modifications of the chromatin (DNA and primarily histones) can regulate gene expression or repression and can be transmitted to the descent (cells or organisms) thanks to an epigenetic memory. These modifications involve histone posttranslational modifications, DNA methylation at CpG islands and small nuclear RNAs processes. They play fundamental roles in cell proliferation and differentiation. These two processes are crucial in particular during embryonic development, X chromosome inactivation in females, genomic imprinting, gene bookmarking, cell reprogramming, position effect and silencing of retroviral elements. While, only one major DNA modification is known, more than 150 post-translation modifications of histones have been reported, including methylations, acetylations, ubiquitinations, SUMOylations and phosphorylations. How these modifications are inherited from mother cells to daughter cells or from an organism to its descent remains a major scientific challenge. We propose here a macro-molecular complex, called ECREM for “Epigenetic Code REplication Machinery”, as being involved in the inheritance of the epigenetic code. The composition of ECREM may vary in a spatio-temporal manner according to the chromatin state, the cell phenotype and the development stage. We describe the members of ECREM, responsible for the epigenetic code inheritance, i.e., enzymes involved in DNA methylation and histone post-translational modifications. Some of them, such as DNA methyltransferases (DNMTs), histone acetyltransferases (HATs) and histone deacetylases (HDACS including sirtuins), have been found to be deregulated in several types of pathologies and are already targeted by inhibitors. ECREM, thus, appears to be an interesting complex to be investigated in order to find new drugs for cancer, metabolic, neuro-degenerative and inflammatory diseases therapy.
Keywords: Cancer, DNA methyltransferase, drug, epigenetic, histone code, histone deacetylases, histone acetyltransferases, inhibitors, neuro-degenerative disorders, sirtuins
Current Medicinal Chemistry
Title: The “Epigenetic Code Replication Machinery”, ECREM: A Promising Drugable Target of the Epigenetic Cell Memory
Volume: 14 Issue: 25
Author(s): Christian Bronner, Thierry Chataigneau, Valerie B. Schini-Kerth and Yves Landry
Affiliation:
Keywords: Cancer, DNA methyltransferase, drug, epigenetic, histone code, histone deacetylases, histone acetyltransferases, inhibitors, neuro-degenerative disorders, sirtuins
Abstract: Discrete chemical modifications of the chromatin (DNA and primarily histones) can regulate gene expression or repression and can be transmitted to the descent (cells or organisms) thanks to an epigenetic memory. These modifications involve histone posttranslational modifications, DNA methylation at CpG islands and small nuclear RNAs processes. They play fundamental roles in cell proliferation and differentiation. These two processes are crucial in particular during embryonic development, X chromosome inactivation in females, genomic imprinting, gene bookmarking, cell reprogramming, position effect and silencing of retroviral elements. While, only one major DNA modification is known, more than 150 post-translation modifications of histones have been reported, including methylations, acetylations, ubiquitinations, SUMOylations and phosphorylations. How these modifications are inherited from mother cells to daughter cells or from an organism to its descent remains a major scientific challenge. We propose here a macro-molecular complex, called ECREM for “Epigenetic Code REplication Machinery”, as being involved in the inheritance of the epigenetic code. The composition of ECREM may vary in a spatio-temporal manner according to the chromatin state, the cell phenotype and the development stage. We describe the members of ECREM, responsible for the epigenetic code inheritance, i.e., enzymes involved in DNA methylation and histone post-translational modifications. Some of them, such as DNA methyltransferases (DNMTs), histone acetyltransferases (HATs) and histone deacetylases (HDACS including sirtuins), have been found to be deregulated in several types of pathologies and are already targeted by inhibitors. ECREM, thus, appears to be an interesting complex to be investigated in order to find new drugs for cancer, metabolic, neuro-degenerative and inflammatory diseases therapy.
Export Options
About this article
Cite this article as:
Bronner Christian, Chataigneau Thierry, Schini-Kerth B. Valerie and Landry Yves, The “Epigenetic Code Replication Machinery”, ECREM: A Promising Drugable Target of the Epigenetic Cell Memory, Current Medicinal Chemistry 2007; 14 (25) . https://dx.doi.org/10.2174/092986707782023244
DOI https://dx.doi.org/10.2174/092986707782023244 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adenovirus-Based Cancer Gene Therapy
Current Gene Therapy RAGE: A Multi-Ligand Receptor Unveiling Novel Insights in Health and Disease
Current Medicinal Chemistry The Therapeutic Potential of Hepatocyte Growth Factor for Myocardial Infarction and Heart Failure
Current Pharmaceutical Design Actual and Potential Agents and Biomarkers in the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Meet Our Regional Editor
Anti-Cancer Agents in Medicinal Chemistry Mutagenic Approaches to Modifying Gap Junction Phenotype
Current Drug Targets Diphenylpentane Skeleton as a Multi-Template for Steroid Skeleton- Recognizing Receptors/Enzymes
Mini-Reviews in Medicinal Chemistry MicroRNA and HER2-overexpressing Cancer
MicroRNA Differences in Antiproliferative Activity Between Salinomycin-AZT Conjugates Obtained via ‘Click’ and Esterification Reactions
Medicinal Chemistry MiR-597 Targeting 14-3-3σ Enhances Cellular Invasion and EMT in Nasopharyngeal Carcinoma Cells
Current Molecular Pharmacology License to Kill Tumors: How Much Hope is Justified for Trail?
Current Pharmaceutical Design Editorial [ Hot Topic-II: Zinc Metallo-Enzymes as Target for Drug Design (Guest Editor: Giuseppina De Simone )]
Current Medicinal Chemistry Human Reduced Folate Carrier Gene and Transcript Variants: Functional, Physiologic, and Pharmacologic Consequences
Current Pharmacogenomics An Overview on Different Classes of Viral Entry and Respiratory Syncitial Virus (RSV) Fusion Inhibitors
Current Medicinal Chemistry Unified Multi-target Approach for the Rational in silico Design of Anti-bladder Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Design of multifunctional nanocarriers for delivery of anti-cancer therapy
Current Pharmaceutical Design Non-Alcoholic Fatty Liver Disease in Children
Current Nutrition & Food Science Editorial [Hot topic: Membrane Estrogen Receptors (Guest Editor: Paul J. Davis)]
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The GNAS Locus: Quintessential Complex Gene Encoding Gsα, XLαs, and other Imprinted Transcripts
Current Genomics Thermodynamic and Kinetic Aspects Involved in the Development of Nanocarriers and Drug Delivery Systems Based on Cationic Biopolymers
Current Pharmaceutical Design